data_1tos_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1tos _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 10.2 m0 . . . . . 0 N--CA 1.479 0.98 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -111.82 134.16 21.4 Favored Pre-proline 0 CA--C 1.56 1.327 0 CA-C-O 118.252 -0.88 . . . . 0.0 109.886 -175.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_exo -46.55 -40.71 23.68 Favored 'Trans proline' 0 CA--C 1.549 1.237 0 N-CA-C 119.839 2.977 . . . . 0.0 119.839 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -66.74 -30.35 70.55 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 115.251 1.575 . . . . 0.0 115.251 177.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -69.28 -16.29 63.54 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 115.824 1.787 . . . . 0.0 115.824 176.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 13.1 m-30 -63.48 133.04 53.23 Favored 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 115.847 1.795 . . . . 0.0 115.847 -164.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.84 -76.17 0.04 OUTLIER Glycine 0 CA--C 1.539 1.563 0 N-CA-C 106.403 -2.679 . . . . 0.0 106.403 178.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -74.21 -53.96 6.57 Favored Glycine 0 CA--C 1.545 1.961 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.061 165.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 56.4 mt -69.54 129.01 33.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 169.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.27 2.168 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -178.279 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' TRP . . . . . 0.423 ' CD2' HG21 ' A' ' 9' ' ' ILE . 25.2 m0 . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 122.068 0.937 . . . . 0.0 110.703 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -111.58 116.57 50.25 Favored Pre-proline 0 CA--C 1.556 1.176 0 CA-C-O 118.061 -0.971 . . . . 0.0 108.841 -176.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_exo -40.34 -40.44 3.04 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 N-CA-C 121.063 3.447 . . . . 0.0 121.063 -177.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.49 -20.51 59.97 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 115.209 1.559 . . . . 0.0 115.209 176.253 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -104.09 56.12 0.72 Allowed 'General case' 0 N--CA 1.483 1.222 0 CA-C-O 122.221 1.01 . . . . 0.0 112.442 -174.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 3.3 m-30 -113.26 171.54 7.49 Favored 'General case' 0 N--CA 1.484 1.248 0 CA-C-O 122.85 1.31 . . . . 0.0 111.337 -174.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.64 -98.51 0.15 Allowed Glycine 0 CA--C 1.532 1.107 0 N-CA-C 107.439 -2.265 . . . . 0.0 107.439 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.85 -34.88 88.58 Favored Glycine 0 CA--C 1.547 2.063 0 C-N-CA 120.919 -0.658 . . . . 0.0 113.137 166.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.423 HG21 ' CD2' ' A' ' 1' ' ' TRP . 66.6 mt -65.61 123.98 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 163.624 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.269 2.111 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 -172.101 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 35.3 m95 . . . . . 0 N--CA 1.477 0.923 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -143.48 132.99 11.68 Favored Pre-proline 0 CA--C 1.552 1.032 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -50.14 -40.4 51.08 Favored 'Trans proline' 0 CA--C 1.544 1.025 0 N-CA-C 118.634 2.513 . . . . 0.0 118.634 -176.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -67.5 -38.52 84.46 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 114.662 1.356 . . . . 0.0 114.662 175.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -74.83 8.49 2.41 Favored 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 115.537 1.68 . . . . 0.0 115.537 176.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 15.9 m-30 -72.6 129.43 38.26 Favored 'General case' 0 N--CA 1.479 1.01 0 O-C-N 120.538 -1.351 . . . . 0.0 112.231 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.46 -75.46 0.04 OUTLIER Glycine 0 N--CA 1.473 1.123 0 N-CA-C 107.811 -2.116 . . . . 0.0 107.811 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -74.01 -52.89 7.47 Favored Glycine 0 CA--C 1.544 1.895 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 164.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.7 mt -71.03 127.74 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 172.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.27 2.143 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.859 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 10.2 m0 . . . . . 0 N--CA 1.479 0.98 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -111.82 134.16 21.4 Favored Pre-proline 0 CA--C 1.56 1.327 0 CA-C-O 118.252 -0.88 . . . . 0.0 109.886 -175.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_exo -46.55 -40.71 23.68 Favored 'Trans proline' 0 CA--C 1.549 1.237 0 N-CA-C 119.839 2.977 . . . . 0.0 119.839 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -66.74 -30.35 70.55 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 115.251 1.575 . . . . 0.0 115.251 177.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -69.28 -16.29 63.54 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 115.824 1.787 . . . . 0.0 115.824 176.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 13.1 m-30 -63.48 133.04 53.23 Favored 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 115.847 1.795 . . . . 0.0 115.847 -164.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.84 -76.17 0.04 OUTLIER Glycine 0 CA--C 1.539 1.563 0 N-CA-C 106.403 -2.679 . . . . 0.0 106.403 178.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -74.21 -53.96 6.57 Favored Glycine 0 CA--C 1.545 1.961 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.061 165.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 56.4 mt -69.54 129.01 33.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 169.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.27 2.168 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -178.279 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' TRP . . . . . 0.423 ' CD2' HG21 ' A' ' 9' ' ' ILE . 25.2 m0 . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 122.068 0.937 . . . . 0.0 110.703 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -111.58 116.57 50.25 Favored Pre-proline 0 CA--C 1.556 1.176 0 CA-C-O 118.061 -0.971 . . . . 0.0 108.841 -176.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_exo -40.34 -40.44 3.04 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 N-CA-C 121.063 3.447 . . . . 0.0 121.063 -177.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.49 -20.51 59.97 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 115.209 1.559 . . . . 0.0 115.209 176.253 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -104.09 56.12 0.72 Allowed 'General case' 0 N--CA 1.483 1.222 0 CA-C-O 122.221 1.01 . . . . 0.0 112.442 -174.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 3.3 m-30 -113.26 171.54 7.49 Favored 'General case' 0 N--CA 1.484 1.248 0 CA-C-O 122.85 1.31 . . . . 0.0 111.337 -174.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.64 -98.51 0.15 Allowed Glycine 0 CA--C 1.532 1.107 0 N-CA-C 107.439 -2.265 . . . . 0.0 107.439 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.85 -34.88 88.58 Favored Glycine 0 CA--C 1.547 2.063 0 C-N-CA 120.919 -0.658 . . . . 0.0 113.137 166.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.423 HG21 ' CD2' ' A' ' 1' ' ' TRP . 66.6 mt -65.61 123.98 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 163.624 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.269 2.111 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 -172.101 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 35.3 m95 . . . . . 0 N--CA 1.477 0.923 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -143.48 132.99 11.68 Favored Pre-proline 0 CA--C 1.552 1.032 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -50.14 -40.4 51.08 Favored 'Trans proline' 0 CA--C 1.544 1.025 0 N-CA-C 118.634 2.513 . . . . 0.0 118.634 -176.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -67.5 -38.52 84.46 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 114.662 1.356 . . . . 0.0 114.662 175.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -74.83 8.49 2.41 Favored 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 115.537 1.68 . . . . 0.0 115.537 176.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 15.9 m-30 -72.6 129.43 38.26 Favored 'General case' 0 N--CA 1.479 1.01 0 O-C-N 120.538 -1.351 . . . . 0.0 112.231 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.46 -75.46 0.04 OUTLIER Glycine 0 N--CA 1.473 1.123 0 N-CA-C 107.811 -2.116 . . . . 0.0 107.811 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -74.01 -52.89 7.47 Favored Glycine 0 CA--C 1.544 1.895 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 164.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.7 mt -71.03 127.74 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 172.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.27 2.143 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.859 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 10.2 m0 . . . . . 0 N--CA 1.479 0.98 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -111.82 134.16 21.4 Favored Pre-proline 0 CA--C 1.56 1.327 0 CA-C-O 118.252 -0.88 . . . . 0.0 109.886 -175.643 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_exo -46.55 -40.71 23.68 Favored 'Trans proline' 0 CA--C 1.549 1.237 0 N-CA-C 119.839 2.977 . . . . 0.0 119.839 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -66.74 -30.35 70.55 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 115.251 1.575 . . . . 0.0 115.251 177.249 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -69.28 -16.29 63.54 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 115.824 1.787 . . . . 0.0 115.824 176.486 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 13.1 m-30 -63.48 133.04 53.23 Favored 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 115.847 1.795 . . . . 0.0 115.847 -164.128 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.84 -76.17 0.04 OUTLIER Glycine 0 CA--C 1.539 1.563 0 N-CA-C 106.403 -2.679 . . . . 0.0 106.403 178.177 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -74.21 -53.96 6.57 Favored Glycine 0 CA--C 1.545 1.961 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.061 165.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 56.4 mt -69.54 129.01 33.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 169.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.27 2.168 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -178.279 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' TRP . . . . . 0.444 ' CD2' HG23 ' A' ' 9' ' ' ILE . 25.2 m0 . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 122.068 0.937 . . . . 0.0 110.703 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -111.58 116.57 50.25 Favored Pre-proline 0 CA--C 1.556 1.176 0 CA-C-O 118.061 -0.971 . . . . 0.0 108.841 -176.141 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_exo -40.34 -40.44 3.04 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 N-CA-C 121.063 3.447 . . . . 0.0 121.063 -177.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.49 -20.51 59.97 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 115.209 1.559 . . . . 0.0 115.209 176.253 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -104.09 56.12 0.72 Allowed 'General case' 0 N--CA 1.483 1.222 0 CA-C-O 122.221 1.01 . . . . 0.0 112.442 -174.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 3.3 m-30 -113.26 171.54 7.49 Favored 'General case' 0 N--CA 1.484 1.248 0 CA-C-O 122.85 1.31 . . . . 0.0 111.337 -174.769 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.64 -98.51 0.15 Allowed Glycine 0 CA--C 1.532 1.107 0 N-CA-C 107.439 -2.265 . . . . 0.0 107.439 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.85 -34.88 88.58 Favored Glycine 0 CA--C 1.547 2.063 0 C-N-CA 120.919 -0.658 . . . . 0.0 113.137 166.44 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.444 HG23 ' CD2' ' A' ' 1' ' ' TRP . 66.6 mt -65.61 123.98 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 163.624 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.269 2.111 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 -172.101 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 35.3 m95 . . . . . 0 N--CA 1.477 0.923 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -143.48 132.99 11.68 Favored Pre-proline 0 CA--C 1.552 1.032 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -50.14 -40.4 51.08 Favored 'Trans proline' 0 CA--C 1.544 1.025 0 N-CA-C 118.634 2.513 . . . . 0.0 118.634 -176.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -67.5 -38.52 84.46 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 114.662 1.356 . . . . 0.0 114.662 175.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -74.83 8.49 2.41 Favored 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 115.537 1.68 . . . . 0.0 115.537 176.402 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 15.9 m-30 -72.6 129.43 38.26 Favored 'General case' 0 N--CA 1.479 1.01 0 O-C-N 120.538 -1.351 . . . . 0.0 112.231 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.46 -75.46 0.04 OUTLIER Glycine 0 N--CA 1.473 1.123 0 N-CA-C 107.811 -2.116 . . . . 0.0 107.811 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -74.01 -52.89 7.47 Favored Glycine 0 CA--C 1.544 1.895 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 164.169 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.7 mt -71.03 127.74 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 172.298 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.27 2.143 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.859 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 10.2 m0 . . . . . 0 N--CA 1.479 0.98 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -111.82 134.16 21.4 Favored Pre-proline 0 CA--C 1.56 1.327 0 CA-C-O 118.252 -0.88 . . . . 0.0 109.886 -175.643 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_exo -46.55 -40.71 23.68 Favored 'Trans proline' 0 CA--C 1.549 1.237 0 N-CA-C 119.839 2.977 . . . . 0.0 119.839 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -66.74 -30.35 70.55 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 115.251 1.575 . . . . 0.0 115.251 177.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -69.28 -16.29 63.54 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 115.824 1.787 . . . . 0.0 115.824 176.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 13.1 m-30 -63.48 133.04 53.23 Favored 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 115.847 1.795 . . . . 0.0 115.847 -164.128 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.84 -76.17 0.04 OUTLIER Glycine 0 CA--C 1.539 1.563 0 N-CA-C 106.403 -2.679 . . . . 0.0 106.403 178.177 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -74.21 -53.96 6.57 Favored Glycine 0 CA--C 1.545 1.961 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.061 165.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 56.4 mt -69.54 129.01 33.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 169.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.27 2.168 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -178.279 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' TRP . . . . . 0.444 ' CD2' HG23 ' A' ' 9' ' ' ILE . 25.2 m0 . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 122.068 0.937 . . . . 0.0 110.703 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -111.58 116.57 50.25 Favored Pre-proline 0 CA--C 1.556 1.176 0 CA-C-O 118.061 -0.971 . . . . 0.0 108.841 -176.141 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_exo -40.34 -40.44 3.04 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 N-CA-C 121.063 3.447 . . . . 0.0 121.063 -177.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.49 -20.51 59.97 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 115.209 1.559 . . . . 0.0 115.209 176.253 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -104.09 56.12 0.72 Allowed 'General case' 0 N--CA 1.483 1.222 0 CA-C-O 122.221 1.01 . . . . 0.0 112.442 -174.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 3.3 m-30 -113.26 171.54 7.49 Favored 'General case' 0 N--CA 1.484 1.248 0 CA-C-O 122.85 1.31 . . . . 0.0 111.337 -174.769 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.64 -98.51 0.15 Allowed Glycine 0 CA--C 1.532 1.107 0 N-CA-C 107.439 -2.265 . . . . 0.0 107.439 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.85 -34.88 88.58 Favored Glycine 0 CA--C 1.547 2.063 0 C-N-CA 120.919 -0.658 . . . . 0.0 113.137 166.44 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.444 HG23 ' CD2' ' A' ' 1' ' ' TRP . 66.6 mt -65.61 123.98 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 163.624 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.269 2.111 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 -172.101 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 35.3 m95 . . . . . 0 N--CA 1.477 0.923 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -143.48 132.99 11.68 Favored Pre-proline 0 CA--C 1.552 1.032 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -50.14 -40.4 51.08 Favored 'Trans proline' 0 CA--C 1.544 1.025 0 N-CA-C 118.634 2.513 . . . . 0.0 118.634 -176.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -67.5 -38.52 84.46 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 114.662 1.356 . . . . 0.0 114.662 175.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -74.83 8.49 2.41 Favored 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 115.537 1.68 . . . . 0.0 115.537 176.402 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 15.9 m-30 -72.6 129.43 38.26 Favored 'General case' 0 N--CA 1.479 1.01 0 O-C-N 120.538 -1.351 . . . . 0.0 112.231 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.46 -75.46 0.04 OUTLIER Glycine 0 N--CA 1.473 1.123 0 N-CA-C 107.811 -2.116 . . . . 0.0 107.811 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -74.01 -52.89 7.47 Favored Glycine 0 CA--C 1.544 1.895 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 164.169 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.7 mt -71.03 127.74 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 172.298 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.27 2.143 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.859 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 10.2 m0 . . . . . 0 N--CA 1.479 0.98 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -111.82 134.16 21.4 Favored Pre-proline 0 CA--C 1.56 1.327 0 CA-C-O 118.252 -0.88 . . . . 0.0 109.886 -175.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_exo -46.55 -40.71 23.68 Favored 'Trans proline' 0 CA--C 1.549 1.237 0 N-CA-C 119.839 2.977 . . . . 0.0 119.839 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -66.74 -30.35 70.55 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 115.251 1.575 . . . . 0.0 115.251 177.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -69.28 -16.29 63.54 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 115.824 1.787 . . . . 0.0 115.824 176.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 13.1 m-30 -63.48 133.04 53.23 Favored 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 115.847 1.795 . . . . 0.0 115.847 -164.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.84 -76.17 0.04 OUTLIER Glycine 0 CA--C 1.539 1.563 0 N-CA-C 106.403 -2.679 . . . . 0.0 106.403 178.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -74.21 -53.96 6.57 Favored Glycine 0 CA--C 1.545 1.961 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.061 165.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 56.4 mt -69.54 129.01 33.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 169.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.27 2.168 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -178.279 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' TRP . . . . . 0.444 ' CD2' HG23 ' A' ' 9' ' ' ILE . 25.2 m0 . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 122.068 0.937 . . . . 0.0 110.703 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -111.58 116.57 50.25 Favored Pre-proline 0 CA--C 1.556 1.176 0 CA-C-O 118.061 -0.971 . . . . 0.0 108.841 -176.141 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_exo -40.34 -40.44 3.04 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 N-CA-C 121.063 3.447 . . . . 0.0 121.063 -177.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.49 -20.51 59.97 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 115.209 1.559 . . . . 0.0 115.209 176.253 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -104.09 56.12 0.72 Allowed 'General case' 0 N--CA 1.483 1.222 0 CA-C-O 122.221 1.01 . . . . 0.0 112.442 -174.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 3.3 m-30 -113.26 171.54 7.49 Favored 'General case' 0 N--CA 1.484 1.248 0 CA-C-O 122.85 1.31 . . . . 0.0 111.337 -174.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.64 -98.51 0.15 Allowed Glycine 0 CA--C 1.532 1.107 0 N-CA-C 107.439 -2.265 . . . . 0.0 107.439 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.85 -34.88 88.58 Favored Glycine 0 CA--C 1.547 2.063 0 C-N-CA 120.919 -0.658 . . . . 0.0 113.137 166.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.444 HG23 ' CD2' ' A' ' 1' ' ' TRP . 66.6 mt -65.61 123.98 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 163.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.269 2.111 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 -172.101 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 35.3 m95 . . . . . 0 N--CA 1.477 0.923 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -143.48 132.99 11.68 Favored Pre-proline 0 CA--C 1.552 1.032 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -50.14 -40.4 51.08 Favored 'Trans proline' 0 CA--C 1.544 1.025 0 N-CA-C 118.634 2.513 . . . . 0.0 118.634 -176.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -67.5 -38.52 84.46 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 114.662 1.356 . . . . 0.0 114.662 175.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -74.83 8.49 2.41 Favored 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 115.537 1.68 . . . . 0.0 115.537 176.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 15.9 m-30 -72.6 129.43 38.26 Favored 'General case' 0 N--CA 1.479 1.01 0 O-C-N 120.538 -1.351 . . . . 0.0 112.231 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.46 -75.46 0.04 OUTLIER Glycine 0 N--CA 1.473 1.123 0 N-CA-C 107.811 -2.116 . . . . 0.0 107.811 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -74.01 -52.89 7.47 Favored Glycine 0 CA--C 1.544 1.895 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 164.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.7 mt -71.03 127.74 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 172.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.27 2.143 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.859 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 10.2 m0 . . . . . 0 N--CA 1.479 0.98 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -111.82 134.16 21.4 Favored Pre-proline 0 CA--C 1.56 1.327 0 CA-C-O 118.252 -0.88 . . . . 0.0 109.886 -175.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_exo -46.55 -40.71 23.68 Favored 'Trans proline' 0 CA--C 1.549 1.237 0 N-CA-C 119.839 2.977 . . . . 0.0 119.839 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -66.74 -30.35 70.55 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 115.251 1.575 . . . . 0.0 115.251 177.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -69.28 -16.29 63.54 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 115.824 1.787 . . . . 0.0 115.824 176.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 13.1 m-30 -63.48 133.04 53.23 Favored 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 115.847 1.795 . . . . 0.0 115.847 -164.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.84 -76.17 0.04 OUTLIER Glycine 0 CA--C 1.539 1.563 0 N-CA-C 106.403 -2.679 . . . . 0.0 106.403 178.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -74.21 -53.96 6.57 Favored Glycine 0 CA--C 1.545 1.961 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.061 165.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 56.4 mt -69.54 129.01 33.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 169.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.27 2.168 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -178.279 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' TRP . . . . . 0.444 ' CD2' HG23 ' A' ' 9' ' ' ILE . 25.2 m0 . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 122.068 0.937 . . . . 0.0 110.703 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -111.58 116.57 50.25 Favored Pre-proline 0 CA--C 1.556 1.176 0 CA-C-O 118.061 -0.971 . . . . 0.0 108.841 -176.141 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_exo -40.34 -40.44 3.04 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 N-CA-C 121.063 3.447 . . . . 0.0 121.063 -177.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.49 -20.51 59.97 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 115.209 1.559 . . . . 0.0 115.209 176.253 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 35.6 t0 -104.09 56.12 0.72 Allowed 'General case' 0 N--CA 1.483 1.222 0 CA-C-O 122.221 1.01 . . . . 0.0 112.442 -174.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 3.3 m-30 -113.26 171.54 7.49 Favored 'General case' 0 N--CA 1.484 1.248 0 CA-C-O 122.85 1.31 . . . . 0.0 111.337 -174.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.64 -98.51 0.15 Allowed Glycine 0 CA--C 1.532 1.107 0 N-CA-C 107.439 -2.265 . . . . 0.0 107.439 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.85 -34.88 88.58 Favored Glycine 0 CA--C 1.547 2.063 0 C-N-CA 120.919 -0.658 . . . . 0.0 113.137 166.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.444 HG23 ' CD2' ' A' ' 1' ' ' TRP . 66.6 mt -65.61 123.98 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 163.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.269 2.111 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 -172.101 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 35.3 m95 . . . . . 0 N--CA 1.477 0.923 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -143.48 132.99 11.68 Favored Pre-proline 0 CA--C 1.552 1.032 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -50.14 -40.4 51.08 Favored 'Trans proline' 0 CA--C 1.544 1.025 0 N-CA-C 118.634 2.513 . . . . 0.0 118.634 -176.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -67.5 -38.52 84.46 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 114.662 1.356 . . . . 0.0 114.662 175.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -74.83 8.49 2.41 Favored 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 115.537 1.68 . . . . 0.0 115.537 176.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 15.9 m-30 -72.6 129.43 38.26 Favored 'General case' 0 N--CA 1.479 1.01 0 O-C-N 120.538 -1.351 . . . . 0.0 112.231 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.46 -75.46 0.04 OUTLIER Glycine 0 N--CA 1.473 1.123 0 N-CA-C 107.811 -2.116 . . . . 0.0 107.811 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -74.01 -52.89 7.47 Favored Glycine 0 CA--C 1.544 1.895 0 N-CA-C 111.432 -0.667 . . . . 0.0 111.432 164.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.7 mt -71.03 127.74 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 172.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.27 2.143 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.859 . . . . . . . . 0 0 . 1 stop_ save_